Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Pharmabiz3d
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...
Analysts Set Nektar Therapeutics (NASDAQ:NKTR) Price Target at $4.08
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. Two ...
FDA grants Fast Track to Nektar's atopic dermatitis drug
SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced today that its drug candidate, rezpegaldesleukin, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ...
Nektar receives FDA Fast Track Designation for rezpegaldesleukin
Therapeutics announced that the U.S. FDA has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and ...
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric ...
Nektar embarks on rejuvenating ‘Mission To Mars’
The 2025 Grammys kicked off with a massive supergroup consisting of the band Dawes, Brittany Howard, St. Vincent, John Legend ...
Nektar Names Kotzin Interim Chief Medical Officer
Nektar Therapeutics named Brian Kotzin its interim chief medical officer, succeeding Mary Tagliaferri, who stepped down from the role citing personal reasons. Kotzin will assist in the search for a ...